[DOI] [PMC free article] [PubMed] [Google Scholar] 36.Woo S-H, Mo YJ, Lee Y-I, Park JH, Hwang D, Park TJ, Kang HY, Park SC, Lee Y-S
Both remain in phase 3 clinical development programs [16]: Cagrilintide Status: Phase 3 trials ongoing for CagriSema (cagrilintide + semaglutide combination) Expected approval timeline: 2027-2028 for the combination product Monotherapy development pathway unclear Retatrutide Status: Phase 3 trials initiated in 2024-2025 Monotherapy development for obesity and metabolic dysfunction Expected approval timeline: 2028-2029 if trials succeed This regulatory status means any use of these compounds, whether individually or in cagrilintide dosage with retatrutide combinations, occurs in research contexts or through off-label prescribing once (if) individual approvals are obtained
In summary, the EGJ is a mobile structure with its mobility dependent upon contractile activity of the longitudinal muscle of the distal esophagus and the integrity/elastic properties of the phrenoesophageal membrane
Both are aligned with standard guidelines approved by regulatory authorities
Stay at each new dose until your appetite, energy, and weight feel stable
